FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:628-630 February 10, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Quagliarello, V. Related Article by Thwaites, G. E. PubMed Citation

To the Editor: The results of the placebo-controlled clinical trial of adjunctive dexamethasone in the treatment of tuberculous meningitis reported by Thwaites et al. (Oct. 21 issue)¹ clearly indicate improved survival in the age group studied — patients more than 14 years of age. Since the percentage of dexamethasone-treated patients who died or had severe disability was not statistically different from that in the control group, one suspects that the patients who survived because of dexamethasone therapy tended to be left with severe disability. One factor not commented on either in the article or in the accompanying editorial by Quagliarello² . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.